{"name":"Otonomy, Inc.","slug":"otonomy-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":125000,"revenueGrowth":-54.2,"grossMargin":0,"rdSpend":34673000,"netIncome":-51181000,"cash":77412000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"OTO-201","genericName":"OTO-201","slug":"oto-201","indication":"Otitis media with effusion in pediatric patients","status":"phase_3"},{"name":"OTO-201 (ciprofloxacin)","genericName":"OTO-201 (ciprofloxacin)","slug":"oto-201-ciprofloxacin","indication":"Acute otitis media with tympanostomy tubes (AOMT)","status":"phase_3"}]}],"pipeline":[{"name":"OTO-201","genericName":"OTO-201","slug":"oto-201","phase":"phase_3","mechanism":"OTO-201 is a sustained-release corticosteroid formulation designed to deliver dexamethasone directly into the middle ear to reduce inflammation and fluid accumulation.","indications":["Otitis media with effusion in pediatric patients"],"catalyst":""},{"name":"OTO-201 (ciprofloxacin)","genericName":"OTO-201 (ciprofloxacin)","slug":"oto-201-ciprofloxacin","phase":"phase_3","mechanism":"OTO-201 is a sustained-release formulation of ciprofloxacin, a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV to kill bacteria in the middle ear.","indications":["Acute otitis media with tympanostomy tubes (AOMT)","Chronic suppurative otitis media (CSOM)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQSzg1LUhmejlya1UyNHlEWDhzNndOWW9aS3Mwa1ozQmw1RkVEMGxPV056bmJXRUNkRzNGSmI1cTlMQTB0dmgxSElEWTJpYlJ5WGs2RXg5dEhuMzU3LVBUVmQwYVBTS3hPNlF6R2sxLVljeHY5SU9tRWRaME11SGlISjZENkNSMGpMR1hZc1hqaUNpSEpKeUx3VmdIZ1ZmWUtWcmk4TE9hbUpnMWhYQ1VybTMwcDU5LWVmNjZGdTF4dm50eFBHSk85TjEzc3hoVUpwdTlXazdacjlfN21tTmFEMGt2eWJ1YnJvNHVvN1ZB?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight - Barchart.com","headline":"Hearing Loss Clinical Trial Pipeline Shows Potential with Active Contributions from 30+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQUDZ6dFZ2eW5wVzBNRXctS1lsNnBCU2Z4Q2YxRDdWaU5JVXR2MU5xTDFyZUIwX1ViWUl0d0V6MkQtekhlRFkzM2lmYXpHR09Fd1MwSEVmdUlPU0FhYnpyVjVaT3VrbVN5aWs3N2EwRDBmb19xOUhES1QyS29Ec09BbVlwVGFzZ3BiV1FQTnktXzJhT25CWHNBeGtvR3NxMXZnbDM3MllwS0NNQVFkcUNrX0VEOGhMWTFQMi0zaUVKbjA5dTRYMmNiOVFTLUUtb0YwSjg4REQ0TWJEcVkwQTltdGtBMUU3NkpOeUMzMWhYVWxyNUFBRXg3WXFIZm1NNnBodTdXQW94bFN6NlVfNTZtUVhQUFVjSVBGVVNzSWRRaXFCcFBlaXhLUg?oc=5","date":"2024-10-30","type":"trial","source":"GlobeNewswire","summary":"Advancements in Sensorineural Hearing Loss Clinical Trial - GlobeNewswire","headline":"Advancements in Sensorineural Hearing Loss Clinical Trial","sentiment":"neutral"},{"date":"2023-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNa3pWX0V5T09KMl9RRkZfbDZSYmlRUTF5cEJjVXI0elZJc3VCVkdadU9QN2pRSHBqSkxOOXk3Q2tkZ3RsWkJoNTVjTzhpRVMwZEl4cnBoeWsyOVhTZ3NXbXFNa1N2bjk0aWlRUHVtVVBNNDJRYjNEQndkanRUbXFtcGFmLUNsOG9aTDJWWWozUUtaQmwyemFzVlNsLTZodU5EaUV6VUwzZUxwVnRhQTB3RmQ3Z0c5Vl90V1JBV2F3NnNneU9BajltcFF5dUx1ZmRlOURaWU1ZaFBsdFNCcFJuWUZZZGlJOVVyZWxhaDZoWm41cHFicEhNODRuM0U4UkVMTjNDeUR1dw?oc=5","date":"2023-03-29","type":"deal","source":"PR Newswire","summary":"Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board - PR Newswire","headline":"Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board","sentiment":"neutral"},{"date":"2023-03-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-02-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZTdCaG9QS2JHazZCbGNHc2NsQjV1enBjMUZYVHpHODRqdDNxMUI2ckdKaWdGUVNDajJKbDRRNVJ0S0R6R3ZEbzY4cFZNOGg4bWhfREdnclhxeTVGanBlYUtvYzcwLXV5dS0zUWVTVWowYmtnMTA4R0VieEFZQ2dGczBoaUxiaEFzV3ZmR3FZcDFJcjlEa1lOWnJ4c05EallXMUM1Z3BMY2hRZw?oc=5","date":"2022-12-20","type":"pipeline","source":"Fierce Biotech","summary":"Otonomy shuts up shop, lays off all employees after string of ear drug failures - Fierce Biotech","headline":"Otonomy shuts up shop, lays off all employees after string of ear drug failures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNWjVzck9NcEpCVGotOUk5MHFieGQtNkxyNGN1dEFnRm9RTDdYNWdNUk96aWlxcC00dEZNeTJkYVFFWkpsM1JSUDhic0dVZms0OEZqN1dNX1NpcjcwdjhQMk9lNmdUSGM3dU5TMEExdjlzNVVPMmpCdk1ncFZ1Q1dkTWNKY25SQQ?oc=5","date":"2022-12-20","type":"pipeline","source":"BioPharma Dive","summary":"Hearing loss biotech Otonomy plans to dissolve - BioPharma Dive","headline":"Hearing loss biotech Otonomy plans to dissolve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNSkZZWEhENXhNLWR1cWFOc1FiSW9fRnlLcmhQT3A3WENtdjAxYmFTV19DU2pvaWpDQVJ0aElWTFlGejBHTGNFVm5ZREd5djB0OWIxc3FRbDhwRVF3X3F6NXpRcThsWWZfME1OQ2NETjBCQ21xNGZKa0ctdi1XY0lLUHpSYkxDWWRsVFpnREVtTXlzVXA1QVFJWGhKeldlNmc?oc=5","date":"2022-12-20","type":"pipeline","source":"Medical Marketing and Media","summary":"Otonomy lays off all employees, begins liquidation process - Medical Marketing and Media","headline":"Otonomy lays off all employees, begins liquidation process","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQTXFsWm4wazNEUU9pODdBcExYc3hCaUZkdUNIaG5ydXdXbXRpelBZdDhUZFFkRGJITzNaQTJhbThyd2ZjbEZTV1VfMWZHemhrUURPdkhPTWk5RWRYbTRxdExzYVJEajBkeXVjVDFKRXFZRzN5V2NnQ1BZcDdwd3lJSm5vSGY0Zw?oc=5","date":"2021-11-13","type":"deal","source":"The Hearing Review","summary":"Otonomy Partners with Kyorin Pharmaceutical on Hearing Loss Compound - The Hearing Review","headline":"Otonomy Partners with Kyorin Pharmaceutical on Hearing Loss Compound","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPc2ZHc2JucURIcV9wWXpCZVdsUXFBX3BjWUtENjE2OGU0OTBzdFFoa0NELUI1RUxPM0dJLU1GWmFhWGc4V2ZGb3dTS1RicnhNNnlUaHhRZGdZZnAxRzBfN0dYUm1RQXdmZnBHeVRIYjR1LXI1aWE0S1NVOU96ZGYzVWEyekNIa2FpbWQyQUhuel9DZ1ZKMlE2RGxjX1k2SGtBOEVHdER6Z0tOQW1yNllYekxpakhxekhoWGcwbDlfZEQ4N1RfaFpIdFRqc3g2Nm03U0lnWFRxbVZ6bEI1?oc=5","date":"2021-06-03","type":"deal","source":"BioSpace","summary":"ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients - BioSpace","headline":"ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxObE9vQjROeXlLZE5fMVNLVnBWSGQwQXM5a3Q4WlB1b2EwLXF0blBNZThRdmZOWW9TTkJBbG85LTlEYnR6WmpTWDRUa1FZS3pjLUhzSEZicHRWZDNvV2MzN2FaYU1EMllyaTJWQUdnV1RDRkdlbk5nYlBneTFfWF81UjRia2tpczI0d0EyWVZjZEpUcm94TGNnNEFhdXBvNkJTNWtGY0Z5MHFtOWhPemJzNmlDalZtY09KOURUVHFHTmltRXRMWjNvZjBTNXd3VDNmWnpxUTBkT01QME0zN1lTNFg5TDVhN2MzcDNFSF8zODBlYjFhazllZmRrajhOTE42NTR4RlU1SzFscXlM?oc=5","date":"2020-08-03","type":"deal","source":"GlobeNewswire","summary":"Otonomy Announces Exclusive License Agreement with Kyorin - GlobeNewswire","headline":"Otonomy Announces Exclusive License Agreement with Kyorin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxONlBaaExOTXVHREdlTlEzaEtBb2ttOTdDbW92YW40aDFCRTdTSzhiczk5LVZIRlVVdlVGREtVeUxtT2dxTjlPS1ZnQUJJUm1QUlVPUlhjVTFheThJRnFvZTdhX0F6amFTcUZRME5BNTY5YnljNTFrOW8zNFd1RkZORXp5Q3R0Nkct?oc=5","date":"2017-09-14","type":"pipeline","source":"Yahoo Finance","summary":"Billionaire Efrem Kamen Pulled Cash From Otonomy Inc (OTIC) and Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Welcoming Gilead Sciences, Inc. (GILD) - Yahoo Finance","headline":"Billionaire Efrem Kamen Pulled Cash From Otonomy Inc (OTIC) and Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Welcomi","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":125000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":125000,"period":"2021-12-31"},{"value":273000,"period":"2020-12-31"},{"value":600000,"period":"2019-12-31"},{"value":745000,"period":"2018-12-31"},{"value":1236000,"period":"2017-12-31"},{"value":683000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":34673000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-51181000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":77412000,"cashHistory":[],"totalAssets":95637000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}